Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis.

摘要

Options for treatment of severe heterozygous and homozygous familial hypercholesterolemia prior to the statin era were limited by significant side effects and morbidity. The advent of both the statins and technology for the selective removal of LDL via apheresis have revolutionized management but challenges remain.